HomeDMYD-B • STO
add
Diamyd Medical AB
Previous close
kr 18.16
Day range
kr 17.88 - kr 18.70
Year range
kr 7.65 - kr 25.00
Market cap
1.88B SEK
Avg Volume
226.52K
P/E ratio
-
Dividend yield
-
Primary exchange
STO
Market news
Financials
Income Statement
Revenue
Net income
| (SEK) | Aug 2024info | Y/Y change |
|---|---|---|
Revenue | 19.00K | -74.32% |
Operating expense | 51.15M | 40.41% |
Net income | -49.74M | -32.60% |
Net profit margin | -261.79K | -416.43% |
Earnings per share | — | — |
EBITDA | -50.48M | -40.02% |
Effective tax rate | — | — |
Balance Sheet
Total assets
Total liabilities
| (SEK) | Aug 2024info | Y/Y change |
|---|---|---|
Cash and short-term investments | 132.37M | 3.79% |
Total assets | 217.04M | 5.46% |
Total liabilities | 71.12M | 95.32% |
Total equity | 145.92M | — |
Shares outstanding | 104.09M | — |
Price to book | 12.44 | — |
Return on assets | -55.84% | — |
Return on capital | -76.10% | — |
Cash Flow
Net change in cash
| (SEK) | Aug 2024info | Y/Y change |
|---|---|---|
Net income | -49.74M | -32.60% |
Cash from operations | -29.16M | 15.53% |
Cash from investing | 18.79M | 886.03% |
Cash from financing | -838.00K | -100.97% |
Net change in cash | -10.27M | -120.46% |
Free cash flow | -18.28M | 27.58% |
About
Diamyd Medical AB is a small biotechnology company headquartered in Stockholm, Sweden that focuses on immune modifying therapies for diabetes. The company is developing two products.
The company is headquartered in Stockholm, and maintains a manufacturing facility in Umeå. Wikipedia
Founded
1984
Website
Employees
28
